Libella Gene Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Libella Gene Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT04133454
- Locations
- 🇨🇴
IPS Arcasalud SAS, Zipaquirá, Cundinamarca, Colombia
Evaluation of Safety and Tolerability of Libella Gene Therapy for the Treatment of Aging: AAV- hTERT
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Libella Gene Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT04133649
- Locations
- 🇨🇴
IPS Arcasalud SAS, Zipaquirá, Cundinamarca, Colombia
Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Libella Gene Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT04110964
- Locations
- 🇨🇴
IPS Arcasalud SAS, Zipaquirá, Cundinamarca, Colombia
News
No news found